Literature DB >> 25855354

An NK Cell Population Lacking FcRγ Is Expanded in Chronically Infected HIV Patients.

Jingling Zhou1, Fathiah S Amran2, Marit Kramski3, Tom A Angelovich4, Julian Elliott5, Anna C Hearps6, Patricia Price2, Anthony Jaworowski7.   

Abstract

We previously demonstrated that NK cells from HIV-infected individuals have elevated expression of activation markers, spontaneously degranulate ex vivo, and decrease expression of a signal-transducing protein for NK-activating receptors, FcRγ. Importantly, these changes were maintained in virologically suppressed (VS) individuals receiving combination antiretroviral therapy (cART). In this study, we show that loss of FcRγ is caused by the expansion of a novel subset of FcRγ(-)CD56(dim) NK cells with an altered activation receptor repertoire and biological properties. In a cross-sectional study, FcRγ(-) NK cells as a proportion of total CD56(dim) NK cells increased in cART-naive viremic HIV-infected individuals (median [interquartile range] = 25.9 [12.6-56.1] compared with 3.80 [1.15-11.5] for HIV(-) controls, p < 0.0001) and in VS HIV-infected individuals (22.7 [13.1-56.2] compared with 3.80 [1.15-11.5], p = 0.0004), with no difference between cART-naive and VS patients (p = 0.93). FcRγ(-) NK cells expressed no NKp30 or NKp46. They showed greater Ab-dependent cellular cytotoxicity activity against rituximab-opsonized Raji cells and in a whole-blood assay measuring NK responses to overlapping HIV peptides, despite having reduced CD16 expression compared with conventional NK cells. Their prevalence correlated with CMV Ab titers in HIV(-) subjects but not in HIV(+) individuals, and with the inflammatory marker CXCL10 in both groups. The expansion of a subset of NK cells that lacks NKp30 and NKp46 to ∼90% of CD56(dim) NK cells in some VS HIV(+) individuals may influence NK-mediated immunosurveillance in patients receiving cART.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25855354     DOI: 10.4049/jimmunol.1402448

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  Natural killer cells in HIV-1 infection and therapy.

Authors:  Joanna Mikulak; Ferdinando Oriolo; Elisa Zaghi; Clara Di Vito; Domenico Mavilio
Journal:  AIDS       Date:  2017-11-13       Impact factor: 4.177

Review 2.  Redefining Memory: Building the Case for Adaptive NK Cells.

Authors:  Silke Paust; Catherine A Blish; R Keith Reeves
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

Review 3.  Memory responses of natural killer cells.

Authors:  Clair D Geary; Joseph C Sun
Journal:  Semin Immunol       Date:  2017-08-30       Impact factor: 11.130

4.  IL-18 Responsiveness Defines Limitations in Immune Help for Specialized FcRγ- NK Cells.

Authors:  Renee R Anderko; Charles R Rinaldo; Robbie B Mailliard
Journal:  J Immunol       Date:  2020-11-13       Impact factor: 5.422

5.  HCMV jogs the 'memory' of NK cells in HBV.

Authors:  Upkar S Gill; Lucy Golden-Mason
Journal:  J Hepatol       Date:  2018-12-11       Impact factor: 30.083

6.  CD56dim CD57- NKG2C+ NK cells retaining proliferative potential are possible precursors of CD57+ NKG2C+ memory-like NK cells.

Authors:  Polina A Kobyzeva; Maria A Streltsova; Sofya A Erokhina; Leonid M Kanevskiy; William G Telford; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 6.011

Review 7.  Natural Killer Cells in Human Immunodeficiency Virus-1 Infection: Spotlight on the Impact of Human Cytomegalovirus.

Authors:  Dimitra Peppa
Journal:  Front Immunol       Date:  2017-10-17       Impact factor: 7.561

8.  High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.

Authors:  Anne-Sophie Chretien; Raynier Devillier; Samuel Granjeaud; Charlotte Cordier; Clemence Demerle; Nassim Salem; Julia Wlosik; Florence Orlanducci; Laurent Gorvel; Stephane Fattori; Marie-Anne Hospital; Jihane Pakradouni; Emilie Gregori; Magali Paul; Philippe Rochigneux; Thomas Pagliardini; Mathieu Morey; Cyril Fauriat; Nicolas Dulphy; Antoine Toubert; Herve Luche; Marie Malissen; Didier Blaise; Jacques A Nunès; Norbert Vey; Daniel Olive
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-01       Impact factor: 11.205

Review 9.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 10.  NK Cells in HIV Disease.

Authors:  Eileen Scully; Galit Alter
Journal:  Curr HIV/AIDS Rep       Date:  2016-04       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.